Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

Blood Cancer Journal
A RosenthalA K Stewart

Abstract

Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore implemented a detailed, prospective, clinical cardiac and renal evaluation of 62 Cfz-treated myeloma patients, including serial blood pressure (BP), creatinine, troponin, NT-proBNP and pre- and post-treatment echocardiograms, including ejection fraction (EF), average global longitudinal strain and compliance. Pre-treatment elevations in NT-proBNP and BP, as well as abnormal cardiac strain were common. A rise in NT-proBNP occurred frequently post-treatment often without corresponding cardiopulmonary symptoms. A rise in creatinine was common, lessened with hydration and often reversible. All patients had a normal EF pre-treatment. Five patients experienced a significant cardiac event (four decline in EF and one myocardial infarction), of which 2 (3.2%) were considered probably attributable to Cfz. None were rechallenged with Cfz. The ideal strategy for identifying patients at risk for cardiac events, and parameters by which to monitor for early toxicity have not been established; however, it appears baseline echocardiographic testing is not consistently predictive of toxicity. The t...Continue Reading

References

Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Jul 10, 2007·Cancer Research·Susan D DemoMark K Bennett
Jun 4, 2010·The American Journal of Pathology·Dominika NowisJakub Golab
Mar 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shirin Arastu-KapurChristopher J Kirk
Jan 25, 2012·Blood·Heinz LudwigUNKNOWN International Myeloma Working Group
Feb 9, 2013·Blood·K Martin Kortuem, A Keith Stewart
Jun 21, 2013·Fundamental & Clinical Pharmacology·Benjamin HontonAtul Pathak
Mar 7, 2014·Annals of Hematology·Ashish SubediBinay Kumar Shah
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators

❮ Previous
Next ❯

Citations

Oct 21, 2016·Expert Opinion on Pharmacotherapy·Maria GavriatopoulouMeletios A Dimopoulos
Nov 30, 2016·Expert Review of Anticancer Therapy·Marco SalviniAlessandra Larocca
Jan 25, 2017·Expert Review of Hematology·Annamaria BrioliMarie Von Lilienfeld-Toal
Mar 10, 2017·Blood·Michel Delforge, Heinz Ludwig
Apr 12, 2017·Antioxidants & Redox Signaling·Carlo Gabriele TocchettiGiuseppe Mercuro
Jan 26, 2017·Cardiovascular Drugs and Therapy·Hai Ying FuTetsuo Minamino
Dec 18, 2016·Clinical Lymphoma, Myeloma & Leukemia·Amit AgarwalSaad Z Usmani
Nov 15, 2017·Expert Opinion on Pharmacotherapy·Dimitrios C ZiogasMeletios A Dimopoulos
Dec 3, 2017·Cancer Metastasis Reviews·Sara GandolfiPaul G Richardson
Dec 14, 2017·Blood Cancer Journal·Tania JainRafael Fonseca
Nov 23, 2017·Expert Review of Cardiovascular Therapy·Pankaj MathurJawahar L Mehta
Aug 18, 2018·Expert Opinion on Drug Safety·Guldane Cengiz Seval, Meral Beksac
Nov 15, 2018·Expert Review of Proteomics·Thomas A Guerrero-GarciaPaul G Richardson
Jun 13, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F CornellDaniel Lenihan
Dec 6, 2018·Cardiovascular & Hematological Disorders Drug Targets·W SerraA Chetta
Jan 4, 2018·Blood Advances·Meletios A DimopoulosEfstathios Kastritis
May 15, 2020·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Tienush RassafUNKNOWN Committee for Clinical Cardiovascular Medicine of the German Cardiac Society
Feb 20, 2016·European Journal of Haematology·Eli MuchtarHila Magen
Oct 28, 2017·Cardiology in Review·Daniel C Cole, William H Frishman
Feb 5, 2019·Internal Medicine·Takenori IkomaYuichiro Maekawa
Jun 10, 2020·Current Oncology Reports·Perry WuEric H Yang
Aug 1, 2020·International Journal of Molecular Sciences·Osamu YamazakiShigeru Shibata
May 11, 2021·Frontiers in Cardiovascular Medicine·Giulia MingroneAlberto Milan
Jun 25, 2021·Therapeutic Advances in Hematology·Andrew J Yee
Apr 14, 2021·Cardiovascular & Hematological Disorders Drug Targets·Azka LatifFaiz Anwer

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01568866
NCT01818752

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Related Papers

The American Journal of Emergency Medicine
Beuy Joob, Viroj Wiwanitkit
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
W F Keane
Trends in Cardiovascular Medicine
Allan S Jaffe, Jaskanwal D Sara
Journal of the American College of Cardiology
Benjamin J FredaGary S Francis
© 2022 Meta ULC. All rights reserved